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RESEARCH ARTICLE 
Abstract 
Meropenem is a third generation broad spectrum antibiotic. Emergence of meropenem resistance has been reported due to 
development of mutant plasmid mediated metallo-β-lactamases (IMP-6) and AmpC β–lactamases. Sulbactam, a stable β-
lactamase inhibitor, increase antimicrobial activity of meropenem by inhibiting the enzyme β-lactamase. Fixed dose 
combination of Meropenem-sulbactam in the proportion of 1:1, 1:2, 1:3, 2:1 and 3:1 were evaluated for the antimicrobial 
activity. Combination of meropenem and sulbactam in the ratio of 2:1 exhibited the synergistic activity. This combination 
was checked for the subchronic toxicity on wistar rats and no change in biochemical and physiological parameters was 
observed. 
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INTRODUCTION 
Since the advent of antibiotic these have been used to 
treat variety of bacterial infection. Prolonged and 
overuse of antibiotics have led to development of 
resistance against the several antibiotic in 
microorganism as a survival strategy. In human 
medicine the major problem of the emergence of 
resistant bacteria is due to misuse and overuse of 
antibiotics by doctors as well as patients. In addition to 
this, use of antibiotics in feed of livestock, household use 
of antibacterial in soaps and other products are some of 
reason which have contributed to development of 
antibiotic resistance. Antibiotic resistance can be a result 
of plasmid or transposons mediated horizontal gene 
transfer and also of unlinked point mutations in the 
pathogen’s genome at a rate of about 1 in 108 per 
chromosomal replication (Yano et al., 2001). 
Microorganisms employ several strategies such as 
intracellular drug inactivation or modification, alteration 
of drug target site, changes in drug metabolic pathway 
and increase in drug efflux to increase the chances of 
survival under meropenem stress (Sinha and Srinivasan, 
2010). Meropenem is one of the broad spectrum 
antibiotics among the carbapenem class therefore 
precautions should be taken to avoid development of 
resistant strain and strategies should be employed before 
the development of resistant strains for benefit of 
mankind. Several instance of appearance of meropenem 
resistant bacterial strains have been reported. The gene 
encoding IMP-6 MBL, a mutant β-lactamase active 
against the meropenem, was first identified in plasmid 
pKU501 from Serratia marcescens KU3838 (Yano et al., 
2001). Since then it has been a major problem for 
meropenem resistant outbreak due to horizontal gene 
transfer (Masuda and Ohya 1992, Nordmann and Poirel 
2002, Ryoo et al., 2009). Combination therapy has long 
been used to treat many infections to increase the 
efficacy of treatment and avoid the development of 
microbial resistance. Combination of antibiotic with β-
lactamases enzyme inhibitor is another fruitful way to 
increase the spectrum of activity of β-lactam antibiotic 
and prevent the emergence of resistance strain. 
Sulbactam has been reported to extend spectrum of 
activity of several antibiotic such as ceftriaxone, 
carbenicillin, cefoperazone and ampicillin (Lim and 
Cheong 1995). Sulbactam has higher stability in the 
solution compared to its counterpart clavulanate. (Wise 
et al., 1980). Keeping in the view clinical significance of 
fixed dose combination of meropenem and sulbactam, 
we planned to study the antimicrobial activity of the 
combination and its safety profile. 
MATERIALS AND METHODS 
Bacterial culture, Pseudomonas aeruginosa ATCC 25619 
and Escherichia coli ATCC 10536 were obtained from Hi-
Media laboratories private limited, India. Lauria Bertani 
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broth and Mueller Hilton broths were procured from 
Sisco Research Laboratories private limited (SRL) India. 
Meropenem carbonate and sulbactam were donated by 
Health Biotech Limited. Meropenem and sulbactam 
fixed dose combinations were prepared in the ratio of 
1:1, 1:2, 1:3, 2:1 and 3:1 by mixing stock solutions of 
meropenem and sulbactam so that final concentration of 
meropenem in combination remained 100 μg/mL. These 
combinations were diluted to prepare the desired range 
of meropenem concentration from 0.2 to 25.0 μg/mL for 
minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration analysis. 
Antimicrobial Activity Analysis 
All of the combinations were prepared in 5% sodium 
carbonate solution in deionized water. These stock 
solutions were diluted with deionized water to prepare 
the dilution for MIC and MBC analysis. Minimum 
inhibitory concentration (MIC), minimum bactericidal 
concentration (MBC), zone of inhibition and time Kill 
study were performed on bacterial strains Pseudomonas 
aeruginosa ATCC 25619 and Escherichia coli ATCC 10536. 
MIC and MBC were determined by double dilution 
technique as per NCCLS M7-A5 guidelines. 
Accordingly, 96-well microtiter plates containing 200 μL 
Muller Hinton (MH) broth (SRL, India) with 
meropenem-sulbactam combination (in the 
concentration range of 0.1-50.0 μg/mL) were inoculated 
with test culture (final cell density of 1 × 105 CFU/mL) 
and incubated at 37 °C for 24 h. The lowest concentration 
of meropenem in the meropenem-sulbactam 
combination showing growth inhibition (as seen 
visually) was considered as the minimum inhibitory 
concentration. The minimum bactericidal concentration 
was recorded as the lowest concentration of meropenem 
in meropenem-sulbactam combination that showed no 
growth on MH agar plates after spot inoculation and 
incubation for 24 h. Assay was performed in triplicate 
with appropriate controls (uninoculated medium, 
meropenem and sulbactam alone). The fractional 
inhibitory concentration index (FICi) for combination 
was determined using Pseudomonas aeruginosa ATCC 
25619 and Escherichia coli ATCC 10536. MIC for each of 
the component was first estimated, and subsequently, 
the fractional inhibitory concentration (FIC) of a 
combination of meropenem and sulbactam was 
calculated (Bharadwaj et al., 2003). 
The FIC was calculated as follows: 
FICA = MICA in combination / MICA 
FICB = MICB in combination / MICB 
Where A = Meropenem, B = Sulbactam 
FICi = FICA + FICB 
The interaction was defined as synergistic if the FICi was 
≤0.5, as partial synergy / additive if the FICi was >0.5 to 
1.0, as indifferent if the FICi was >1.0 to 2.0, and as 
antagonistic if the FICi was >2.0. 
Time kill study was performed on both bacterial strains. 
The cultures were inoculated in 2 mL of MH broth (final 
cell density of 1 × 105 CFU/mL) supplemented with 
meropenem-sulbactam combinations (at concentrations 
corresponding to 3 x MIC) and incubated for 8 h. 
Aliquots (0.1 mL) were removed at hourly intervals, 
serially diluted, and total viable counts on MH agar 
plates were determined after incubation at 37 °C for 24 h. 
Kill curves were constructed by plotting the log CFU 
against time. 
Subchronic Toxicity Analysis 
Subchronic toxicity study was performed with 
meropenem-sulbactam in 2:1 proportion. Healthy Wistar 
rats of either sex were divided into four groups and 
assigned as three treatment groups and one control 
group. All groups consist of 6 male and 6 female 
animals. Animals were provided with standard pellet 
diet and water was given ad libitum. They were housed 
in polyurethane cages (three in each) at controlled room 
temperature of 29 ± 2°C and a relative humidity of 
50.5%, with a constant light-dark schedule (12 hours 
light and 12 hour dark cycle). 
Animals were given freshly prepared intravenous 
injection of Meropenem-sulbactam for 28 days. The 
mixture of Meropenem-sulbactam was prepared in 0.9 % 
NaCl before administration and was injected at 
following dose levels; Group I –Control group, Group II 
100 mg/kg, Group III 200 mg/kg and Group IV 400 
mg/kg. Control group was injected 0.9 % NaCl only. 
Dosing was done approximately at the same time on 
each day. All the animals were observed for physical, 
biochemical and hematology alterations. Overnight 
fasted animals were sacrificed; blood and tissues 
samples were collected on 29th day. Hemogram was 
performed on Hematolgy Analyzer (Sysmax K 1000). For 
histopathological analysis liver, kidney, stomach, Heart 
and Lungs were removed from the sacrificed animals 
and were preserved in 10 % buffered formalin. Serum 
Gluatmic oxaloacetic transaminase (SGOT), Serum 
Gluatmic pyruvic transaminase activities (SGPT), 
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Alkaline phosphatase (ALP), Blood urea nitrogen (BUN) 
and plasma sugar levels were estimated on biochemistry 
analyzer using diagnostic kits (Robonik ASP-300). 
Dunnett's test was used for the evaluation of data and P 
<0.05 accepted as significant. 
RESULTS AND DISCUSSIONS 
Meropenem and sulbactam fixed dose combination 
exhibited greater antimicrobial activity compared to 
meropenem alone. Meropenem-sulbactam combination 
in the proportion of 2:1 showed bacterial growth 
inhibition for E. coli and Pseudomonas aeruginosa up to 35 
hours effectively as compared to meropenem alone 
(Figure 1 & 2). Physical combination resulted in fast 
decrease in CFU per ml for first 6 hours, they maintained 
low CFU upto 24 hours and then slow increase in CFU 
per ml was seen as compared to meropenem alone. In 
case of meropenem alone CFU increased faster after 24 
hours. There was decrease in MBC from 1.0 µg/mL to 
0.8 µg/mL for E.coli and 4.0 µg/mL to 2.0 µg/mL for 
Pseudomonas aeruginosa for meropenem to sulbactam 
combination in proportion of 2:1. This combination has 
FICi value close to 0.5 and was found to behave 
synergistically as shown in Table-1.  
Table 1. Nature of interaction of fix dose combination 
Organism 
MIC of 
meropenem 
MIC 
sulbactam 
MIC of 
combination 
in ratio of 2:1 
FICi 
Value 
Nature of   
interaction 
E. coli 0.40 25 0.30 0.76 Partial synergy 
P. aeruginosa 1.0 50 0.40 0.40 Synergistic 
 
Meropenem-sulbactam combination of 2:1 was checked 
for subchronic toxicity in wistar rats at dosages of 100 
mg/kg, 200 mg/kg and 400 mg/kg for 28 days. No 
behavioral changes were observed throughout the 
dosing period. No significant change group mean body 
weight was observed in all the groups as compared to 
control group on 29th day. In male and female rat 
groups, no significant change was observed in 
hemoglobin (Hb), red blood cell counts (RBC), Rt 
(Reticulocyte), hematocrit (HCT), mean corpuscular 
volume (MCV), mean cell haemoglobin (MCH), mean 
cell corpuscular hemoglobin concentration (MCHC) 
,white blood cell (WBC) counts and platelet counts in all 
the treated groups as compared to respective control 
groups (Table 2 & 3). 
Figure 1. Time kill curve of meropenem-sulbactam combination and 
controls for Pseudomonas aeruginosa (M-Meropenem, S-Sulbactum) 
Figure 2. Time kill curve of meropenem-sulbactam combination and 
controls for E. coli (M-Meropenem, S-Sulbactum) 
 
Further there was no significant change in SGOT, SGPT 
and SAP activities in all the treated groups as compared 
to respective control group. Serum proteins and Blood 
sugar levels were comparable treated and control groups 
(Table 4 & 5). This establishes the safety of meropenem 
sulbactam combination. SGOT, SGPT and SAP are 
critical indicator for hepatotoxicity in addition other 
hematological parameters. 
Meropenem is used to treat several bacterial infections 
such as urinary tract infections, pneumonia, sepsis, intra-
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abdominal infections, skin and soft-tissue infections, 
meningitis and nosocomial infections (Huizinga et al., 
1995, Mouton and Beuscart 1995, Hsu et al., 2001).  
 
Table 2. Effect on hemogram in male rats 
Gr.  No. 
Dose 
mg/kg 
Hb  (%) 
Total RBC 
(x10
6
/cmm) 
Rt (%) HCT (%) MCV µm
3
 MCH(pg) MCHC (%) 
Platelets 
(10
5
/cmm) 
Total WBC) 
x10
3
/cmm 
I Control 15.22 ± 1.72 5.55±0.53 1.65±0.46 52.00±5.55 66.92±8.09 20.27±3.71 33.18±2.97 5.40±1.74 6.63±1.23 
II 100 15.02 ±1.65 6.17±0.88 1.68±0.29 50.17±6.82 63.43±7.99 18.97±2.91 31.73±2.14 5.35±1.28 7.30±1.04 
III 200 12.74±0.73 5.83±1.04 1.75±0.31 47.67±4.23 60.20±6.35 16.89±0.70 32.35±1.80 6.56±0.80 6.43±0.76 
IV 400 12.47±0.43 6.31±0.48 1.82±0.45 46.50±3.94 59.90±3.17 16.19±0.92 33.55±3.09 5.93±0.72 5.97±0.67 
Values are represented as Mean±SD, n=6.  
Table 3. Effect on hemogram in female rats 
Gr.No Dose (mg/kg) Hb (%) 
Total RBC 
(x10
6
/cmm) 
Rt (%) HCT (%) MCV (μm
3
) MCH(pg) MCHC (%) 
Platelets 
(/10
5
cmm) 
Total WBC 
(x10
3
/cmm) 
I Control 16.43±1.22 5.90±0.53 1.45±0.41 54.00±5.62 63.57±6.07 21.03±4.11 32.37±2.27 6.20±0.53 6.92±1.14 
II 100 13.20±0.88 5.95±0.86 1.70±0.36 50.33±7.34 62.80±7.38 17.88±1.87 32.83±2.62 5.85±1.14 6.43±0.76 
III 200 12.96±0.70 6.07±0.67 1.70±0.49 45.50±5.32 60.04±3.25 16.35±0.71 32.64±2.33 6.22±0.71 6.13±0.69 
IV 400 12.47±0.41 6.02±0.58 1.70±0.42 42.42±2.38 59.70±2.16 16.03±0.93 34.66±3.37 5.89±0.74 6.06±0.19 
Values are represented as Mean±SD, n=6 
Table 4. Effect on biochemical parameters in male rats 
Gr. No. Dose (mg/kg) TSP (g%) BUN (mg%) SGPT (IU/L) SGOT (IU/L) SAP (IU/L) Blood Sugar (mg%) 
I Control 7.75±0.29 33.80±2.32 89.52±8.82 91.50±5.01 402.33±96.67 95.48±6.37 
II 100 7.65±0.29 30.82±2.61 67.67±11.72 92.83±8.11 447.00±49.25 98.40±7.22 
III 200 7.60±0.27 30.41±2.90 96.03±6.86 94.87±8.58 412.67±53.05 100.23±4.89 
IV 400 7.48±0.40 40.43±6.3 80.17±12.64 92.50±9.7 428.33±40.01 98.67±5.77 
Values are represented as Mean±SD, n=6 
Table 5: Effect on Biochemical parameters in female rats 
Gr. No. Dose (mg/kg) TSP (g%) BUN (mg%) SGPT (IU/L) SGOT (IU/L) SAP (IU/L) Blood Sugar (mg%) 
I Control 7.74±0.42 32.78±3.83 71.17±15.42 89.67±8.55 420.33±37.73 97.98±3.91 
II 100 7.59±0.43 30.78±4.12 66.83±12.54 92.00±6.26 413.17±35.10 94.77±5.96 
III 200 7.53±0.46 30.48±1.98 86.00±14.56 90.53±6.43 428.17±48.44 97.90±3.27 
IV 400 7.40±0.35 31.23±3.12 80.00±12.13 88.33±6.68 419.17±29.78 100.90±5.69 
Values are represented as Mean±SD, n=6 
It is also a promising antibiotic in the treatment of 
hospitalized infants and children with serious infections 
because of its broad spectrum antibacterial activity. 
Meropenem has been approved by United States Food 
and Drug Administration (US-FDA) for use in pediatric 
meningitis and severe infections in intensive care 
settings. Meropenem and sulbactam combination as well 
as Meropenem, sulbactam and colistin three drug 
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combinations has been reported to exhibit the synergistic 
effect on multidrug resistant Acenetobacter baumannii 
isolates. Lee CM et al have reported the role of sulbactam 
combination with carbapenem and second or third 
generation cephalosporins, antipseudomonas penicillins, 
or fluoroquinolones with aminoglycosides on Pan-drug 
resistant (PDRAB) Acinetobacter baumannii. They found 
that 30 % of bacteria turned sensitive to imipenem in 
presence of sulbactam (Lee et al., 2005). As per 
Meropenem Yearly Susceptibility Test Information 
Collection (MYSTIC) report, Meropenem demonstrate 
good activity against Enterobacteriaceae, including strains 
producing ESBLs or AmpC (100% for E coli, 99% for 
other Enterobacteriaceae), meropenem usually being 2 to 4 
fold more potent than imipenem ( Pfaller and Ronald 
2000, Laure et al., 2010, Hernández et al 2006) and 
susceptibility of Acinetobacter was close 94-98%. 
The antibacterial activity of Meropenem results from 
inhibition of the bacterial cell synthesis. It readily 
penetrates through the cell wall of Gram positive as well 
as Gram negative bacteria to reach the penicillin binding 
protein target. Its greatest efficiency is for PBP 2 of 
Escherichia coli, PBP 2 and 3 of Pseudomonas aeruginosa 
and PBP 1, 2 and 4 of Staphylococcus aureus. Meropenem 
being susceptible to enzyme beta-lactamase and 
carbapenemases (Cécile et al., 2005) produced by the 
bacteria need to be protected from degradation by these 
enzymes. Sulbactam is an irreversible inhibitor of most 
of common beta-lactamase except amp C 
cephalosporinases. It binds the enzyme and does not 
allow it to interact with the antibiotic. 
CONCLUSION 
This study offers an unequivocal proof that meropenem 
and sulbactam combination act as a potent antimicrobial 
combination at ratio of 2:1 respectively. In vivo 
biochemical and hematological experiments established 
the safety of the combination. Hence this combination 
provides sustainable solution for antimicrobial 
chemotherapy. 
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